SV 2024
DOI: 10.22514/sv.2024.014
|View full text |Cite
|
Sign up to set email alerts
|

A review on increasing risk for gastrointestinal bleeding associated with dabigatran

Abstract: Dabigatran, a reversible direct thrombin inhibitor, is widely used in clinical practice as a therapeutic option due to its unique mechanism of action in comparison to other anticoagulants. Although patients taking dabigatran experience a reduced risk of fatal bleeding, a higher risk of gastrointestinal bleeding (GIB) is associated with dabigatran, and its rational use between anticoagulation and bleeding is challenging for clinicians. To prevent GIB, it is imperative for clinicians to understand the pharmacolo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 59 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?